pING-hHER3FL
/ Duke University
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
July 03, 2025
Assessing the Immunogenicity of pING-hHER3FL
(clinicaltrials.gov)
- P1 | N=10 | Active, not recruiting | Sponsor: Herbert Lyerly | Recruiting ➔ Active, not recruiting | N=24 ➔ 10 | Trial completion date: Aug 2026 ➔ Mar 2030 | Trial primary completion date: Aug 2025 ➔ Mar 2026
Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date • Esophageal Cancer • Oncology • ERBB3
February 24, 2025
Assessing the Immunogenicity of pING-hHER3FL
(clinicaltrials.gov)
- P1 | N=24 | Recruiting | Sponsor: Herbert Lyerly | Trial completion date: Jan 2026 ➔ Aug 2026 | Trial primary completion date: Jan 2025 ➔ Aug 2025
Trial completion date • Trial primary completion date • Esophageal Cancer • Oncology • ERBB3
September 20, 2024
Assessing the Immunogenicity of PING-hHER3FL
(clinicaltrials.gov)
- P1 | N=24 | Recruiting | Sponsor: Herbert Lyerly | Trial completion date: Sep 2025 ➔ Jan 2026 | Trial primary completion date: Sep 2024 ➔ Jan 2025
Trial completion date • Trial primary completion date • Esophageal Cancer • Gastrointestinal Cancer • Oncology • ERBB3
March 22, 2024
Assessing the Immunogenicity of pING-hHER3FL
(clinicaltrials.gov)
- P1 | N=24 | Recruiting | Sponsor: Herbert Lyerly | Trial completion date: Mar 2025 ➔ Sep 2025 | Trial primary completion date: Mar 2024 ➔ Sep 2024
Trial completion date • Trial primary completion date • Esophageal Cancer • Gastrointestinal Cancer • Oncology • ERBB3
October 27, 2023
Assessing the Immunogenicity of pING-hHER3FL
(clinicaltrials.gov)
- P1 | N=24 | Recruiting | Sponsor: Herbert Lyerly | Trial completion date: Dec 2024 ➔ Mar 2025 | Trial primary completion date: Dec 2023 ➔ Mar 2024
Trial completion date • Trial primary completion date • Esophageal Cancer • Gastrointestinal Cancer • Oncology • ERBB3
1 to 5
Of
5
Go to page
1